Topiramate potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice

European Journal of Pharmacology

Volumn 388, Issue 2, 2000, Pages 163-170

  De Sarro, Giovambattista ^a   Gratteri, Santo ^a   Bonacci, Federico ^b   Musumeci, Sebastiano A ^c   Elia, Maurizio ^c   De Sarro, Angela ^d  

^a Faculty of Medicine   (Italy)

^b ASL 7   (Italy)

^c OASI RESEARCH INSTITUTE IRCCS   (Italy)

^d UNIVERSITY OF MESSINA   (Italy)

Author keywords

Anticonvulsant; Audiogenic seizure; Carbamazepine; DBA 2 mouse; Epilepsy; Felbamate; Phenytoin; Topiramate; Valproate

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DIAZEPAM; FELBAMATE; LAMOTRIGINE; PHENOBARBITAL; PHENYTOIN; TOPIRAMATE; VALPROATE MAGNESIUM; VALPROIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; AUDIOGENIC SEIZURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG POTENTIATION; FEMALE; MALE; MOTOR PERFORMANCE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEIZURE;

ACOUSTIC STIMULATION; ANIMALS; ANTICONVULSANTS; BODY TEMPERATURE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; FEMALE; FRUCTOSE; MALE; MICE; MICE, INBRED DBA; MOTOR ACTIVITY; MUSCULOSKELETAL EQUILIBRIUM; SEIZURES;

EID: 0033984914     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00779-7     Document Type: Article

References (55)

1. Ben-Menachem E. Potential antiepileptic drugs: topiramate. Levy R.H., Mattson R.M., Meldrum B.S. Antiepileptic Drugs. 4th edn. 1995;1063-1670 Raven Press, New York.
2. Ben-Menachem E., Henriksen O., Dam M., Mikkelsen M., Schmidt D., Reid S., Reife R., Kramer L., Pledger G., Karim R. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia. 37:1996;539-543.
3. Bourgeois B.F.D. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia. 36(5):1995;S1-S7.
4. Britton J.W., So E.L. New antiepileptic drugs: prospects for the future. J. Epilepsy. 8:1995;267-281.
5. Brown S.D., Wolf H.H., Swinyard E.A., Twyman R.E., White H.S. The novel anticonvulsant topiramate enhances GABA-mediated chloride flux. Epilepsia. 34:1993;122-123.
6. Coulter D.A., Sombati S., De Lorenzo R.J. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia. 34:1993;123.
7. Coulter D.A., Sombati S., De Lorenzo R.J. Topiramate effects on excitatory amino acid-mediated responses in cultured hippocampal neurons: selective blockade of kainate currents. Epilepsia. 36:1995;S40.
8. De Sarro G.B., Croucher M.J., Meldrum B.S. Anticonvulsant actions of DS 103-282: pharmacological studies in rodents and the baboon, Papio papio. Neuropharmacology. 23:1984;526-530.
9. De Sarro G.B., De Sarro A., Trimarchi G.R., Nisticò G. Effects of some calcium antagonists upon the activity of common antiepileptic compounds on sound-induced seizures in DBA/2 mice. Gen. Pharmacol. 23:1992;75-82.
10. De Sarro G.B., Nava F., Aguglia U., De Sarro A. Lamotrigine potentiates the antiseizure activity of some anticonvulsants in DBA/2 mice. Neuropharmacology. 35:1996;153-158.
11. De Sarro G.B., Spagnolo C., Gareri P., Gallelli L., De Sarro A. Gabapentin potentiates the antiseizure activity of certain anticonvulsants in DBA/2 mice. Eur. J. Pharmacol. 349:1998;179-185.
12. Doose D.E., Walker S.A., Pledger G., Lim P., Reife R.A. Evaluation of phenobarbital and primidone/phenobarbital (primidone's active metabolite) plasma concentrations during administration of add-on topiramate therapy in five multicenter, double-blind, placebo-controlled trials in outpatients with partial seizures. Epilepsia. 36:1995;S158.
13. Dunham N.W., Miya T.S. A note on a simple apparatus for detecting neurological deficit in rats and mice. J. Am. Pharm. Assoc. 46:1957;208-209.
14. Edmonds H.L., Jiang D., Zhang P., Vaught J.L. Topiramate in a rat model of posttraumatic epilepsy. Epilepsia. 32:1991;15.
15. Edmonds H.L. Jr., Jiang D., Zhang Y.P., Shank R.P., Johnson R.W. Topiramate as a neuroprotectant and anticonvulsant in postischemic injury. Epilepsia. 33:1992;118-119.
16. Faught E. Efficacy of topiramate as adjunctive therapy in refractory partial seizures: United States trial experience. Epilepsia. 38:1997;S24-S27.
17. Gardocki J.F., Labinsky L.S., Brown G.L., Maryanoff B.E. Anticonvulsant activity of McN-4853 (M) 2,3:4,5-bis-O-(L-methylethylidene)-β-D-fructopyranose sulfamate in mice and rats. Epilepsia. 27:1986;648-649.
18. Gisclon L.G., Curtin C.R., Kramer L.D. The steady-state (SS) pharmacokinetics (PK) of phenytoin (Dilantin) and topiramate (Topamax) in epileptic patients on monotherapy and during combination therapy. Epilepsia. 35:1994;54.
19. Glauser T.A. Topiramate. Sem. Pediatr. Neurol. 4:1997;34-42.
20. Gordey M., Delorey T.M., Olsen R.W. Topiramate modulates GABA receptor responses in Xenopus oocytes expressing several recombinant receptor subunit combinations. Epilepsia. 36:1995;48.
21. Graves N.M., Leppik I.E. Advances in pharmacotherapy: recent developments in the treatment of epilepsy. J. Clin. Pharmacol. Ther. 18:1993;227-242.
22. Hanaya R., Sasa M., Ujihara H., Ishihara K., Serikawa T., Iida K., Akimitsu T., Arita K., Kurisu K. Suppression by topiramate of epileptiform burst discharges in hippocampal CA3 neurons of spontaneously epileptic rat in vitro. Brain Res. 789:1998;274-282.
23. Harden C.L. New antiepileptic drugs. Neurology. 44:1994;787-795.
24. Heater D., Langtry H.D., Gillis J.C., Davis R. Topiramate, a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs. 54:1997;752-773.
25. Jiang D., Zhang P., Vaught J.L. Topiramate in a rat model of posttraumatic epilepsy. Epilepsia. 32:1991;15.
26. Kimishima K., Wang Y., Tanabe K. Anticonvulsant activities and properties of topiramate. Jpn. J. Pharmacol. 58:1992;211P.
27. Leach J.P. Polypharmacy with anticonvulsants. Focus on synergism. CNS Drugs. 8:1997;366-375.
28. Levy R.H., Bishop F., Streeter A.J., Trager W.F., Kunze K.L., Thummel K.T., Mather G.G. Explanation and prediction of drug interactions with topiramate using a CYP450 inhibit spectrum. Epilepsia. 36:1995;47.
29. Litchfield J.T., Wilcoxon F. A simplified method of evaluating dose-effect experiments. J. Pharmacol. Exp. Ther. 96:1949;99-113.
30. Macdonald R.L., Meldrum B.S. Principles of antiepileptic drug action. Levy R.H., Mattson R.H., Meldrum B.S. Antiepileptic Drugs. 4th edn. 1995;61-77 Raven Press, New York.
31. Maryanoff, B.E., Gardocki, J.F., 1985. Anticonvulsant sulfamate derivatives. U.S. Patent No. 4, 513, 006.
32. Maryanoff B.E., Margul B.L. Topiramate. Drugs Future. 14:1989;342-343.
33. Maryanoff B.E., Nortey S.O., Gardocki J.F., Shank R.P., Dodgson S.P. Anticonvulsant O-alkyl sulfamates. 2,3:4,5-bis-O-(1-methylethylydiene)-β-D-fructopyranose sulfamate and related compounds. J. Med. Chem. 30:1987;880-887.
34. McLean M.J., MacDonald R.L. Sodium valproate, but not ethosuximide, produces use and voltage-dependent limitation of high frequency repetitive firing of action potentials of mouse central neurons in cell culture. J. Pharmacol. Exp. Ther. 244:1986;789-795.
35. Meldrum B.S. Amino acid neurotransmitters and new approaches to anticonvulsant drug action. Epilepsia. 25:1984;S140-S149.
36. Meldrum B.S. Identification and preclinical testing of novel antiepileptic compounds. Epilepsia. 38:1997;S7-S15.
37. Nakamura J., Tanura S., Kanda T., Ishii A., Ishihara K., Sarikawa T., Yamada J., Sasa M. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur. J. Pharmacol. 254:1994;83-89.
38. Privitera M. Topiramate: a new antiepileptic drug. Ann. Pharmacother. 31:1997;1164-1173.
39. Rizzo M., Morrone L., Longo P., Sinopoli V.A., Spagnolo C., Lo Pilato R., Pelaggi T., David E., Rotiroti D.A., De Sarro G. Simultaneous determination of lamotrigine, felbamate and some conventional antiepileptic drugs using high-performance liquid chromatography. Pharmacol. Res. 35:1997;105.
40. Rosenfeld W.E. Topiramate: a review of preclinical, pharmacokinetic and clinical data. Clin. Ther. 19:1997;1294-1308.
41. Rosenfeld W.E., Doose D.R., Walker S.A. The steady-state pharmacokinetics of topiramate as adjunctive therapy in pediatric subjects with epilepsy. Epilepsia. 36:1995;158.
42. Rosenfeld W.E., Liao S., Kramer L.D., Anderson G., Palmer M., Levy R.H., Nayak R.K. Comparison of the steady-state pharmacokinetics of topiramate and valproate in patients with epilepsy during monotherapy and concomitant therapy. Epilepsia. 38:1997;324-333.
43. Rosenfeld W.E., Sachdeo R.C., Faught R.E., Privitera M. Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: retrospective survey of open-label treatment. Epilepsia. 38:1997;S34-S36.
44. Shank R.P., Vaught J.L., Raffa R.B., Maryanoff B.E. Investigation of the mechanism of topiramate's anticonvulsant activity. Epilepsia. 32:1991;7-8.
45. Shank R.P., Gardocki J.F., Vaught J.L., Davis C.B., Schupsky J.J., Raffa R.B., Dodgson S.J., Nortey S.O., Maryanoff B.E. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia. 32:1994;450-460.
46. 2+-induced seizures discharges in cultured hippocampal neurons. Epilepsia. 36:1995;38.
47. Swinyard E.A., Woodhead J.H., White H.S., Franklin M.R. General principles: experimental selection, quantification and evaluation of anticonvulsants. Levy R., Mattson R.M., Meldrum B.S., Penry J.K., Dreifuss F.E. Antiepileptic Drugs. 3rd edn. 1989;85-102 Raven Press, New York.
48. Tassinari C.A., Michelucci R., Chauvel P., Chodkiewicz J., Shorvon S., Henriksen O., Dam M., Reife R., Pledger G., Karim R. Double-blind, placebo-controlled trial of topiramate (600 mg daily) for the treatment of refractory partial epilepsy. Epilepsia. 37:1996;763-768.
49. + current fractions by the new anticonvulsant topiramate. J. Pharmacol. Exp. Ther. 288:1999;960-968.
50. Upton N. Mechanism of action of new antiepileptic drugs: rationale design and serendipitous findings. TINS. 15:1994;456-463.
51. Vaught J.L., Maryanoff B.E., Shank R.P. The pharmacological profile of topiramate: a structurally novel, clinically effective anticonvulsant. Epilepsia. 32:1991;19.
52. Wauquier A., Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res. 24:1996;73-77.
53. White H.S. Clinical significance of animal seizure models and mechanism of action studies of potential antiepileptic drugs. Epilepsia. 38:1997;S9-S17.
54. White H.S., Brown S.D., Skeen G.A., Twyman R.E. The investigational topiramate potentiates GABA-evoked currents in mouse cortical neurons. Epilepsia. 36:1995;34.
55. White H.S., Brown D., Skeen G.A., Wolf H.H., Twyman R.E. The anticonvulsant topiramate displays a unique ability to potentiate GABA-evoked chloride currents. Epilepsia. 36:1995;S39-S40.